Skip to main content

Table 3 Combination index (CI) for cell viability in GBM cell lines U-251 MG and U-343 MG treated with BKM120/PQR309 and URMC-099 (n = 3)

From: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation

BKM120 (μM)

PQR309 (μM)

URMC-099 (μM)

CI* in U-251 MG cells

CI in U-343 MG cells

BKM120 + URMC-099

PQR309 + URMC-099

BKM120 + URMC-099

PQR309 + URMC-099

0.5

1

0.75

1.3989 ± 0.2163

1.5254 ± 0.3801

4.7114 ± 0.2524

1.1346 ± 0.0512

1

2

1.5

1.4334 ± 0.1484

1.4664 ± 0.2958

3.6418 ± 0.8218

1.9790 ± 0.0174

2

4

3

1.1565 ± 0.2646

0.8072 ± 0.0409

2.9486 ± 0.6378

1.7963 ± 0.2530

3

6

4.5

0.8357 ± 0.0579

0.6518 ± 0.0092

1.2952 ± 0.5308

0.8334 ± 0.1518

4

8

6

1.1241 ± 0.1438

1.0504 ± 0.1408

0.9371 ± 0.0928

0.8804 ± 0.0166

5

10

7.5

1.6589 ± 0.2057

1.8739 ± 0.1506

1.1621 ± 0.0186

1.1876 ± 0.0811

  1. * Data were presented as mean ± S.E.M. CI < 0.9 indicates synergistic effects; CI > 1.1 indicates antagonistic effects; CI between 0.9 and 1.1 indicates additive effects